KLRC1 and neoplasm: In this context, clinical trials are presently undergoing in which anti-NKG2A (monalizumab) or anti-KIR (lirilumab) antibodies are used as a combotherapy with anti PD-1 (nivolumab) for various type of solid tumors in order to obtain a complete reconstitution of anti-tumor NK cell citolytic activity (71).